ストックスクリーナーアプリを入手
1.93
3.02%
-0.06
アフターアワーズ：
2.14
0.21
+10.88%
前日終値:
$1.99
開ける：
$1.98
24時間の取引高:
10,999
Relative Volume:
0.78
時価総額：
$4.71M
収益：
$3,000
当期純損益:
$-4.11M
株価収益率:
-0.8899
EPS:
-2.1688
ネットキャッシュフロー:
$-3.23M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
-7.66%
6か月 パフォーマンス:
-24.90%
1年 パフォーマンス:
-19.58%
1日の値動き範囲:
$1.93
$1.98
1週間の範囲:
$1.9086
$2.0199
52週間の値動き範囲:
$1.67
$4.59
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
名前
Alaunos Therapeutics Inc
セクター
電話
(346) 355-4099
住所
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
1.93 | 4.88M | 3,000 | -4.11M | -3.23M | -2.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
Alaunos Therapeutics Inc (TCRT) 最新ニュース
Ziopharm: Q2 Earnings Snapshot - 10TV
Alaunos Therapeutics, Inc. Q2 2026: Revenue $0K, Net loss $988K, EPS $(0.41) — 10-Q Summary - TradingView
Alaunos Therapeutics (TCRT) warns on cash runway, Nasdaq compliance and losses - Stock Titan
Alaunos Therapeutics (TCRT) CEO granted 4,363 shares in lieu of cash salary - Stock Titan
Enterprise value to EBITDA forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEO Holger Weis takes Alaunos Therapeutics, Inc. (TCRT) stock instead of salary - Stock Titan
Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant - Stock Titan
Alaunos Therapeutics (TCRT) director gets 8,789-share equity grant in lieu of fees - Stock Titan
Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees - Stock Titan
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alaunos Therapeutics Inc (TCRT) Cash Flow - TradingKey
Alaunos Therapeutics Inc (TCRT) Balance Sheet - TradingKey
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Alaunos Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRT|Alaunos Therapeutics Inc|Price:1.940|Chg%:+0.020 - TradingKey
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alaunos Therapeutics (TCRT) Edges Higher as Stock Holds Above Key SupportMACD Signal Stocks - dars.gov.et
Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to book forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
Enterprise value to revenue forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to sales forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Inc. (TCRT) Q4 2023 Earnings: EPS Misses Expectations as Pre‑Revenue Biotech Struggles - dars.gov.et
MSN Money - MSN
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Stock grant to Alaunos (TCRT) CEO issued in lieu of salary - Stock Titan
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical DevelopmentEarnings Per Share - dars.gov.et
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver - The National Law Review
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study - markets.businessinsider.com
Alaunos Reports New Preclinical Liver Data for ALN1003 - TipRanks
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market SessionUniverse Pharmaceuticals (NASDAQ:UPC), Deco - Benzinga
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT) - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Ongoing Clinical DevelopmentEstimate Dispersion - dars.gov.et
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
TCRT Q4 2023 Earnings: EPS Miss Reflects Clinical-Stage Operational HeadwindsNew Analyst Coverage - dars.gov.et
Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TCRT Q4 2023 Earnings: EPS Miss Amid Ongoing Clinical DevelopmentEarnings Surprise Report - newsline.com
Number of shareholders of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates, No Revenue Reported, Stock DeclinesEarnings Stability Report - newsline.com
Alaunos Therapeutics (TCRT) Declines 6.56% as Stock Tests Key Support Near $2.17Swing Trade Setups - newsline.com
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss on Lack of RevenueEstimate Dispersion - dars.gov.et
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk - Bez Kabli
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Alaunos Therapeutics (TCRT) Declines 4.18% as Biotech Sector Pressure Tests Key Support LevelsQuality ETF - newsline.com
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Continued Clinical-Stage Cash BurnGuidance Update - dars.gov.et
Alaunos Therapeutics Inc (TCRT) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):